Envafolimab (Synonyms: ASC 22; KN 035) |
| カタログ番号GC66344 |
Envafolimab (ASC 22; KN 035) は、ヒト化単一ドメイン抗 PD-L1 抗体の組換えタンパク質です。 Envafolimab は、抗 PD-L1 ドメインとヒト IgG1 抗体の Fc フラグメントとの融合によって作成されます。 Envafolimab は、PD-L1 と PD-1 の間の相互作用を 5.25nm の IC50 値でブロックします。エンバフォリマブは抗腫瘍活性を示します。 Envafolimab は、固形腫瘍の研究の可能性を秘めています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2102192-68-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nm. Envafolimab shows antitumor activity. Envafolimab has the potential for the research of solid tumors[1][2][3].
Envafolimab (0-2.51 nM) induces T-cell cytokine (IFN-γ) production in a dose- and time-dependent manner[3].
Envafolimab (0.18-0.92 mg/kg; i.p.; four times over 2 weeks) shows antitumor activity with a half-life of ~72 h in NOD-SCID mice (A375 cells)[3].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *